HUSSMAN STRATEGIC ADVISORS, INC.
Position in COLL — Collegium Pharmaceutical, Inc
CIK 1179475
ELLICOTT CITY, MD
Position in COLL
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$3,472,350
+$2,569,875 QoQ
Shares Held
105,000
+233.3% QoQ
Ownership
0.323%
of shares outstanding
% of Portfolio
0.76%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2020
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in COLL Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026HUSSMAN STRATEGIC ADVISORS, INC. holds $14,720,685 across 7 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
27,300 | $4,601,142 | |
| 2 | ANIP |
Ani Pharmaceuticals Inc
|
31,500 | $2,607,570 | |
| 3 | ALKS |
Alkermes plc.
|
42,000 | $2,200,800 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
210,000 | $2,100,000 | |
| 5 | PAHC |
Phibro Animal Health Corp
|
42,000 | $1,318,800 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
2,100 | $1,137,843 | |
| 7 | ZTS |
Zoetis Inc.
|
10,500 | $754,530 |
All Filings in COLL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,472,350 | 105,000 | Shares | Sole | 2026-05-11 | |
| 2024-12-31 | $902,475 | 31,500 | Shares | Sole | 2025-02-03 | |
| 2024-09-30 | $1,622,880 | 42,000 | Shares | Sole | 2024-11-01 | |
| 2020-09-30 | $2,123,640 | 102,000 | Shares | Sole | 2020-11-02 | |
| No filing history on record for this holder in this stock. | ||||||